Sernova Corp., a clinical-stage regenerative medicine therapeutics company, is pleased to announce it has completed the acquisition of cellular local immune protection technology from Converge Biotech, Inc. (“Converge”).

This acquisition is a strategic accelerator for expansion of Sernova’s total regenerative medicine cell therapy therapeutics platform. Local immune protection technologies to cloak therapeutic cells have the potential to protect cells from immune system attack within Sernova’s Cell Pouch™ through different and independent mechanisms to eliminate the need for life-long immunosuppression medications.

Dr. Philip Toleikis, Sernova’s President and Chief Executive Officer

Pursuant to the asset acquisition, Sernova acquired all intellectual property associated with Converge’s conformal coating cell encapsulation technology (“Conformal Coating Technology”), including issued patents, patent applications, and know-how.